NCT06739226View on ClinicalTrials.gov

Combination Immunotherapy Targeting Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Melanoma
Interventions
BIOLOGICAL

Antigen-specific CAR T, CTL and DCvac to treat melanoma.

Antigen-specific CAR T, CTL and DCvac to treat melanoma.

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-Immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER

NCT06739226 - Combination Immunotherapy Targeting Melanoma | Biotech Hunter | Biotech Hunter